Fenofibrate, an agonist of PPARα, is a useful therapeutic option for patients with dyslipidemias, particularly those associated with diabetes mellitus or coronary heart disease, and metabolic syndrome [32, 33]. The gene discussed is PPARA; the disease is metabolic syndrome.